SANOFI-ADR (SNY) Stock Fundamental Analysis
USA - NASDAQ:SNY - US80105N1054 - ADR
49.63 USD
+0.74 (+1.51%)
49.63 USD
0 (0%)
Taking everything into account, SNY scores 6 out of 10 in our fundamental rating. SNY was compared to 192 industry peers in the Pharmaceuticals industry. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth Finally SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
SNY had a positive operating cash flow in the past year.
SNY had positive earnings in each of the past 5 years.
In the past 5 years SNY always reported a positive cash flow from operatings.
1.2 Ratios
SNY has a better Return On Assets (11.05%) than 92.71% of its industry peers.
The Return On Equity of SNY (19.73%) is better than 90.63% of its industry peers.
SNY has a better Return On Invested Capital (13.84%) than 92.19% of its industry peers.
SNY had an Average Return On Invested Capital over the past 3 years of 7.31%. This is significantly below the industry average of 13.48%.
The last Return On Invested Capital (13.84%) for SNY is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
Looking at the Profit Margin, with a value of 20.35%, SNY belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
SNY's Profit Margin has improved in the last couple of years.
SNY has a better Operating Margin (23.59%) than 89.58% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
SNY has a Gross Margin of 71.70%. This is in the better half of the industry: SNY outperforms 77.60% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SNY is creating value.
SNY has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for SNY remains at a similar level compared to 5 years ago.
SNY has a better debt/assets ratio than last year.
2.2 Solvency
SNY has a debt to FCF ratio of 2.21. This is a good value and a sign of high solvency as SNY would need 2.21 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.21, SNY belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
SNY has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.21, SNY is in line with its industry, outperforming 45.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.86
WACC7.46%
2.3 Liquidity
A Current Ratio of 1.27 indicates that SNY should not have too much problems paying its short term obligations.
SNY's Current ratio of 1.27 is on the low side compared to the rest of the industry. SNY is outperformed by 77.60% of its industry peers.
SNY has a Quick Ratio of 1.27. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SNY (0.94) is worse than 77.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -5.35% in the last year.
Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
The Revenue has been growing slightly by 2.56% in the past year.
Measured over the past years, SNY shows a small growth in Revenue. The Revenue has been growing by 3.31% on average per year.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 7.06% on average per year.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 4.52% on average per year.
EPS Next Y3.07%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
EPS Next 5Y7.06%
Revenue Next Year0.53%
Revenue Next 2Y3.48%
Revenue Next 3Y4.4%
Revenue Next 5Y4.52%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.33 indicates a reasonable valuation of SNY.
Compared to the rest of the industry, the Price/Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 88.54% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of SNY to the average of the S&P500 Index (25.45), we can say SNY is valued rather cheaply.
The Price/Forward Earnings ratio is 10.04, which indicates a very decent valuation of SNY.
Based on the Price/Forward Earnings ratio, SNY is valued cheaply inside the industry as 86.98% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of SNY to the average of the S&P500 Index (34.46), we can say SNY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.33 | ||
| Fwd PE | 10.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 96.35% of the companies listed in the same industry.
90.10% of the companies in the same industry are more expensive than SNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.43 | ||
| EV/EBITDA | 5.63 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNY does not grow enough to justify the current Price/Earnings ratio.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.7
PEG (5Y)2.22
EPS Next 2Y5.75%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.33%, SNY is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 7.07, SNY pays a better dividend. On top of this SNY pays more dividend than 96.35% of the companies listed in the same industry.
SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.33% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
49.63
+0.74 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.5%
Inst Owner Change-5.61%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap120.90B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price Target61.86 (24.64%)
Short Float %0.25%
Short Ratio1.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.33% |
Yearly Dividend2.21
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)-2.99%
PT rev (3m)-3.27%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)-7.4%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)-5.41%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.97%
Revenue NY rev (1m)0.96%
Revenue NY rev (3m)-0.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.33 | ||
| Fwd PE | 10.04 | ||
| P/S | 1.55 | ||
| P/FCF | 10.43 | ||
| P/OCF | 9.23 | ||
| P/B | 1.5 | ||
| P/tB | 11.3 | ||
| EV/EBITDA | 5.63 |
EPS(TTM)4.38
EY8.83%
EPS(NY)4.94
Fwd EY9.96%
FCF(TTM)4.76
FCFY9.59%
OCF(TTM)5.38
OCFY10.84%
SpS32.09
BVpS33.09
TBVpS4.39
PEG (NY)3.7
PEG (5Y)2.22
Graham Number57.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.46%
ROIC/WACC1.86
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y3.07%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
EPS Next 5Y7.06%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year0.53%
Revenue Next 2Y3.48%
Revenue Next 3Y4.4%
Revenue Next 5Y4.52%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year30.73%
EBIT Next 3Y13.89%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
What is the valuation status for SNY stock?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What is the valuation of SANOFI-ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 11.33 and the Price/Book (PB) ratio is 1.5.
Can you provide the financial health for SNY stock?
The financial health rating of SANOFI-ADR (SNY) is 4 / 10.